Navigation Links
Nanotechnology Could Revolutionize Cardiac Treatment

Scientists have developed nanomolcecules called ‘nanolipoblockers’ that guard against bad cholesterol. The molecules are designed in such a way that they offer a local therapeutic effect,// aimed at reducing the recurrence of blocked blood vessels in cardiac patients. These nanoengineered molecules, which represent the first line of defense against harmful cholesterol could soon join the fight against heart disease, perhaps even help prevent it in high-risk individuals.

In a paper scheduled for publication June 12 in the American Chemical Society's journal Biomacromolecules and now appearing on that journal's Web site, Rutgers researchers propose a way to combat clogged arteries by attacking how bad cholesterol triggers inflammation and causes plaque buildup at specific blood vessel sites. Their approach contrasts with today's statin drug therapy, which aims to reduce the amount of low-density lipids, or LDLs (‘bad’ cholesterol), throughout the body.

In an ironic twist, the Rutgers approach aims to thwart a biological process that is typically beneficial and necessary. Prabhas Mogue, the principal investigator and associate professor of biomedical engineering and chemical and biochemical engineering at Rutgers, said that vascular plaque and inflammation develop when certain forms of LDL are attacked by white blood cells that scavenge cellular debris and disease agents. ‘While these scavengers, called macrophages, perform an essential role in keeping organisms healthy, their interaction with highly oxidized LDL molecules has quite the opposite effect,’ he said.

Mogue explains that macrophages accumulate large amounts of oxidized LDL and secrete chemicals that can damage the neighboring tissues and, ultimately, become fatty foam cells. The researchers' approach, therefore, is to create clusters of nanoengineered molecules that target specific receptor molecules on cell membranes and block these oxidized LDLs from attaching to macrop hages.

Mogue is working with Kathryn Uhrich, Rutgers professor of chemistry and chemical biology, who is an expert at synthesizing biologically useful molecules at the nanoscale – anywhere from 10 to 100 nanometers long. The research team, which also includes graduate student Evangelia Chnari and synthetic chemists Lu Tian and Jinzhong Wang, has designed a family of nanolipoblockers, or NLBs, which compete with oxidized LDL for a macrophage's attention. The NLBs bind to receptor sites on macrophages, cutting the accumulation of oxidized LDL by as much as 75 percent.

The NLB particles are made of several engineered organic strands or chains whose ends cluster around a central point, creating a structure known as a micelle. Uhrich synthesized molecule chains with several different characteristics, such as attracting or repelling water or having a positive or negative charge. When the chains assembled into micelles, Mogue tested them for how well they blocked LDL uptake.

‘We're employing the tools of nanotechnology – specifically tailoring the structure of the molecule, changing groups on the ends of the chains and closely analyzing which forms of the particles bind to the different macrophage receptors,’ Uhrich said. ‘The significant finding of our study is that the nanoscale organization matters tremendously for blockage of oxidized LDL, which opens new avenues for more specific targeting of receptors.’

Mogue said that if this method proves feasible in living organisms, it could convey treatment to the site of the problem, rather than a systemic approach. ‘While statins are a great stride in preventing cardiovascular disease, they are not suitable for everyone,’ Mogue said. ‘Our approach also has potential to topically address the recurrence of inflammation and blockage at stent surgery sites, something that systemically active drugs have not been shown to consistently do.’

Research to test the performance of NLBs in living organisms is now under way.

Soure: Eurekalert
'"/>




Related medicine news :

1. CoQ10 bioavailability increased by Nanotechnology
2. Nanotechnology Revolution To Be Spearheaded By European Union
3. RNA Nanotechnology To Rescue Cancer Patients In Future
4. Scientists Consider About New Technology Called Nanotechnology
5. Potential Benefits Of New Nanotechnology
6. Nanotechnology Promises Huge Medical Benefits
7. Nanotechnology at its best: Nanomotors And Mechanical Nanoswitches
8. Anti-Sense Drugs and Nanotechnology Offer New Hope In Cancer Fight
9. Nanotechnology – to detect and treat ovarian cance
10. Nanotechnology Used For Detecting Viruses
11. India, China Trying to Fight Disease With Nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, Doctors on ... to help personal injury victims find high quality medical care. When the company started ... area. Fast forward to present day and the now ten-page directory features a vast ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) Portland ... autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being launched ... other caregivers the opportunity to share stories and advice, seek help, and continue their ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... inspirational interview of two ostomy patients, standing as living proof that attitude and ... from digestive diseases and issues that spike around the holidays. This campaign will ...
(Date:12/2/2016)... Delaware (PRWEB) , ... December 02, 2016 , ... ... released a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps ... sample entry through labeling, storing, shipping and disposal. The new version is a ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ... and night. No other wearable health technology on the market can deliver all that ... poeple more meaningful insights about their health than the usual heart rate and steps ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016  The Addiction Treatment Advisory ... of Managed Care Pharmacy (AMCP), has released detailed ... address the opioid addiction crisis, including through improved ... ATAG,s newly released paper, "The Role ... Naloxone," addresses many issues around gaps and barriers ...
(Date:12/2/2016)...  Maxor National Pharmacy Services, LLC ("Maxor"), today announced that ... The combination of Texas -based Maxor Specialty ... bring together both company,s clinical expertise and high-touch patient service ... specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... -- CVS Health Corporation (NYSE: CVS ) ... December 15, 2016, beginning at 8:00 a.m. (ET). Senior members ... in-depth review of the company,s strategies to drive long-term ... discuss 2017 earnings guidance during the event. ... be broadcast simultaneously on the Investor Relations portion of ...
Breaking Medicine Technology: